Literature DB >> 15801914

Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer?

J P Gisbert1, J M Pajares.   

Abstract

AIMS: To systematically review the efficacy on ulcer healing of 1-week combination of a proton pump inhibitor plus two antibiotics and to perform a meta-analysis of randomized clinical trials to evaluate whether 7 days of proton pump inhibitor-based triple therapy is sufficient to heal peptic ulcer.
METHODS: Studies where 1-week proton pump inhibitor-based triple therapy was administered to heal peptic ulcer were included. Randomized clinical trials comparing the efficacy on ulcer healing of 7-day proton pump inhibitor-based triple therapy versus this same regimen but prolonging the proton pump inhibitor for several more weeks were included in the meta-analysis. Electronic and manual bibliographical searches were conducted. Meta-analysis was performed combining the odds ratios of the individual studies.
RESULTS: Twenty-four studies (2342 patients) assessed ulcer healing with 1-week proton pump inhibitor-based triple therapy. Mean healing rate was 86%, and 95% in Helicobacter pylori-eradicated patients. Six studies (862 patients), were included in the meta-analysis. Mean ulcer healing rate with a 7-day treatment was 91% versus 92% when proton pump inhibitor was prolonged for 2-4 more weeks (odds ratio = 1.11; 95% confidence interval = 0.71-1.74).
CONCLUSION: In patients with peptic ulcer and H. pylori infection, prolonging therapy with proton pump inhibitor after a triple therapy for 7 days with a proton pump inhibitor and two antibiotics is not necessary to induce ulcer healing.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15801914     DOI: 10.1111/j.1365-2036.2005.02418.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  13 in total

Review 1.  Proton pump inhibitors: an update of their clinical use and pharmacokinetics.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-08-05       Impact factor: 2.953

2.  Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan.

Authors:  Tsutomu Nishida; Masahiko Tsujii; Hirohisa Tanimura; Shusaku Tsutsui; Shingo Tsuji; Akira Takeda; Atsuo Inoue; Hiroyuki Fukui; Toshiyuki Yoshio; Osamu Kishida; Hiroyuki Ogawa; Masahide Oshita; Ichizo Kobayashi; Shinichiro Zushi; Makoto Ichiba; Naoto Uenoyama; Yuichi Yasunaga; Ryu Ishihara; Mamoru Yura; Masato Komori; Satoshi Egawa; Hideki Iijima; Tetsuo Takehara
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

3.  Evidence-based clinical practice guidelines for peptic ulcer disease 2015.

Authors:  Kiichi Satoh; Junji Yoshino; Taiji Akamatsu; Toshiyuki Itoh; Mototsugu Kato; Tomoari Kamada; Atsushi Takagi; Toshimi Chiba; Sachiyo Nomura; Yuji Mizokami; Kazunari Murakami; Choitsu Sakamoto; Hideyuki Hiraishi; Masao Ichinose; Naomi Uemura; Hidemi Goto; Takashi Joh; Hiroto Miwa; Kentaro Sugano; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2016-02-15       Impact factor: 7.527

Review 4.  Pathogenesis of Helicobacter pylori infection.

Authors:  Johannes G Kusters; Arnoud H M van Vliet; Ernst J Kuipers
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

5.  [Clinical practice guideline on the management of patients with dyspepsia. Update 2012].

Authors:  Javier P Gisbert; Xavier Calvet; Juan Ferrándiz; Juan Mascort; Pablo Alonso-Coello; Mercè Marzo
Journal:  Aten Primaria       Date:  2012-10-01       Impact factor: 1.137

6.  Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial.

Authors:  Akira Terano; Tetsuo Arakawa; Toshiro Sugiyama; Hidekazu Suzuki; Takashi Joh; Toshikazu Yoshikawa; Kazuhide Higuchi; Ken Haruma; Kazunari Murakami; Kenzo Kobayashi
Journal:  J Gastroenterol       Date:  2007-08-24       Impact factor: 7.527

7.  A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate.

Authors:  Joongyub Lee; KyungEun Youn; Nam-Kyong Choi; Jin-Ho Lee; DongYoon Kang; Hong-Ji Song; Byung-Joo Park
Journal:  J Gastroenterol       Date:  2013-01-11       Impact factor: 7.527

8.  One week of esomeprazole triple therapy vs 1 week of omeprazole triple therapy plus 3 weeks of omeprazole for duodenal ulcer healding in Helicobacter pylori-positive patients.

Authors:  Iyad M Subei; Hector José Cardona; Ernesto Bachelet; Emerson Useche; Anthony Arigbabu; Adnan Abu Hammour; Tom Miller
Journal:  Dig Dis Sci       Date:  2007-04-27       Impact factor: 3.487

9.  A review of rabeprazole in the treatment of acid-related diseases.

Authors:  Fabio Pace; Stefano Pallotta; Stefania Casalini; Gabriele Bianchi Porro
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

Review 10.  Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression.

Authors:  Carmelo Scarpignato; Luigi Gatta; Angelo Zullo; Corrado Blandizzi
Journal:  BMC Med       Date:  2016-11-09       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.